Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Key Companies Innovating in GLP-1 Obesity Treatments In 2025, the landscape of obesity treatment is being reshaped by innovative companies developing GLP-1 (glucagon-like peptide-1) receptor agonists
2025;9(5):e2401171
Since starting semaglutide, Ive noticed that I have a lot less bloat and my weight has been very stable with almost no fluctuations
Diabetes Metab 43(5):430437 Nslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ et al (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
For more on typical intake patterns, see our guide on eating too little on Mounjaro
The Core Issue: Failure to Warn Patients of Severe Risks The central argument in the GLP-1 lawsuits is that manufacturers like Novo Nordisk and Eli Lilly knew, or should have known, about the risk of severe side effects like stomach paralysis and bowel obstruction but failed to adequately warn doctors and patients
